ORION Biotech Catalyst Calendar
Menu
Skip to content

Incyte (INCY) · povorcitinib

Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.

Before

Stated timing: 2026

data from the Phase 2 proof-of-concept trial in asthma, are anticipated in 2026

EX-99.1 · filed · SEC filing

After

Stated timing: second half of 2026

data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026

EX-99.1 · filed · SEC filing

Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.

Source: ORION, orionbiotechai.com/changes/INCY-povorcitinib-2026-02-10, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/INCY-povorcitinib-2026-02-10

Incyte (INCY) pipeline and stated timing · Calendar · Companies A–Z